Coloplast


Multiple silver linings in spite of a soft Q2 24

15/05/24 -"Coloplast reported softer than expected Q2 24 figures. However, with healthy organic growth, the miss reflected FX headwinds, and, hence, was not that worrisome. Importantly, growth was strong across ..."

Pages
63
Language
English
Published on
15/05/24
You may also be interested by these reports :
17/05/24
Clariane communicated more details regarding its projected capital increases and the entry of a new anchor shareholder in its capital. We take this ...

17/05/24
We have incorporated the detailed information provided by Clariane regarding its projected capital increases. This has resulted in only minor changes ...

16/05/24
On the back of the promising beginning to 2024, which was a combination of 1/ normalising market demand in Europe (the lynchpin geography); 2/ the ...

16/05/24
As we have consistently argued over the last 3 years, Health stocks (ex Pharma) are long on growth promises and short on delivery. The gap stems from ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO